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A course of treatment with narrow-band ultraviolet 
B (NB-UVB) improves psoriasis and increases serum 
25-hydroxyvitamin D (25(OH)D). In this study 12 pa-
tients with psoriasis who were supplemented with oral 
cholecalciferol, 20 µg daily, were given a course of NB-
UVB and their response measured. At baseline, serum 
25(OH)D was 74.14 ± 22.9 nmol/l. At the 9th exposure to 
NB-UVB 25(OH)D had increased by 13.2 nmol/l (95% 
confidence interval (95% CI) 7.2–18.4) and at the 18th 
exposure by 49.4 nmol/l (95% CI 35.9–64.6) above base-
line. Psoriasis Area Severity Index score improved from 
8.7 ± 3.5 to 4.5 ± 2.0 (p < 0.001). At baseline, psoriasis le-
sions showed low vitamin D metabolizing enzyme (CY-
P27A1, CYP27B1) and high human β-defensin-2 mRNA 
expression levels compared with those of the healthy 
subjects. In conclusion, NB-UVB treatment significantly 
increases serum 25(OH)D in patients with psoriasis who 
are taking oral vitamin D supplementation, and the con-
centrations remain far from the toxicity level. Healing 
psoriasis lesions show similar mRNA expression of vita-
min D metabolizing enzymes, but higher antimicrobial 
peptide levels than NB-UVB-treated skin in healthy sub-
jects. Key words: psoriasis; ultraviolet B radiation; vitamin 
D; CYP27A1; CYP27B1; cathelicidin; human β-defensin.
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Vitamin D insufficiency is common in Europe and North 
America, especially during the winter when vitamin D 
synthesis induced by sunlight is zero (1, 2). The desirable 
concentration of serum 25-hydroxyvitamin D (25(OH)
D), which is the best indicator of vitamin D status, is 
still under debate. A concentration below 75 nmol/l (30 
ng/ml) is considered to be insufficient for bone fracture 
prevention (3). In addition to osteoporosis, low serum 
25(OH)D concentration has recently been associated with 
risk of colorectal cancer and cardiovascular disease (4, 
5). Vitamin D is also known to affect skin inflammation 
and innate or adaptive immune responses (6, 7). 
Recent studies suggest that vitamin D insufficiency is 
also common in patients with psoriasis (8–10). Gisondi 
et al. (8) found that, in Italy in winter, serum 25(OH)D 
was below 50 nmol/l in 81% of patients with psoriasis 
compared with 30% of healthy controls. They also sho-
wed that vitamin D insufficiency was associated with 
psoriasis independently of age, sex and body mass index 
(BMI). Romaní et al. (10) concluded that the insuffi-
ciency was also common in patients with psoriasis and 
controls in Spain, but in their study carefully matched 
controls had a higher insufficiency rate than patients 
with psoriasis.
Narrow-band UVB (NB-UVB) phototherapy, a wi-
dely used effective treatment for psoriasis (11), suppres-
ses interferon-gamma (IFN-γ) and interleukin (IL)-17 
signalling pathways to resolve psoriatic inflammation 
(12). NB-UVB light emitting at 311–313 nm is also 
capable of activating vitamin D synthesis in cultured 
keratinocytes (13). Moreover, several studies have 
shown that, in addition to healing of psoriasis, NB-
UVB treatment significantly increases serum 25(OH)D 
(14–17), and this increase correlates with the activation 
of circulating regulatory T cells (18). 
Interestingly, the expression of cathelicidin, which 
is one of the most important antimicrobial peptides in 
human skin, is dependent on 1,25-dihydroxyvitamin 
D (1,25(OH)2D) and is triggered by UVB-induced vi-
tamin D metabolism (6, 19). Cathelidicin and another 
inducible cutaneous antimicrobial peptide, human 
β-defensin-2 (HBD2), can act as immune-regulating 
effectors or “alarmins” and link adaptive and innate 
immune responses (20). In addition, these antimicro-
bial peptides seem to have a role in the control of skin 
inflammation in psoriasis (21, 22).
The present study examined whether NB-UVB treat-
ment can increase serum 25(OH)D in patients with pso-
riasis who are already supplemented with oral vitamin 
D. In addition, we investigated the effects of NB-UVB 
exposure on cutaneous mRNA expression of vitamin 
D-metabolizing enzymes and antimicrobial peptides. 
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METHODS 
Patients with psoriasis and healthy subjects
A total of 12 patients with psoriasis (mean age 42.8 years; Table 
I) participated in the study. Four patients had also psoriatic 
arthritis, but none of them received any systemic drug treatment 
because their arthritis was not active during the study. Inclu-
sion criteria were no phototherapy, solarium or sunny holidays 
during the 2 preceding months. Before the NB-UVB course the 
patients had used cholecalciferol 20 µg (800 IU) daily for a 
mean of 3.3 months (Table I). Fifteen nurses and other hospital 
employees (mean age 46.1 years; Table I) volunteered as con-
trols in the study. These subjects had used oral cholecalciferol 
for a mean of 3.4 months (Table I). The patients with psoriasis 
and the healthy subjects continued to use oral cholecalciferol 
during the NB-UVB course and subsequent to it. 
The study protocol was approved by the ethics committee 
of Tampere University Hospital and all subjects gave their 
informed consent to participate. The study protocol followed 
the principles of the Declaration of Helsinki.
Narrow-band UVB exposure
The study was performed in winter from December 2011 to April 
2012 in order to exclude the effect of the sun. The study subjects 
received NB-UVB exposure 3 times a week on the whole body 
area with a Waldmann UV 7001 cabin equipped with 40 TL01 
tubes (Schulze & Böhm, Brühl, Germany). The first NB-UVB 
dose was 0.19 J/cm2 (1.11 standard erythema dose (SED)) and it 
was gradually increased each time, according to a fixed protocol, 
up to 9 exposures, i.e. to 0.97 J/cm2 (5.70 SED). If the subjects 
experienced mild itching or erythema, the next NB-UVB dose 
was either not increased or was reduced. This was the case in 
6 patients with psoriasis and 8 healthy subjects. Thereafter, the 
NB-UVB treatment was given only to patients with psoriasis until 
the rash was almost or totally cleared. This took a mean of 20.5 
(range 11–31) NB-UVB exposures. Clinical improvement was 
measured with the Psoriasis Area Severity Index (PASI) score.
The mean cumulative dose of NB-UVB given to the 12 patients 
with psoriasis during 9 exposures was 4.49 ± 0.44 J/cm2 and to the 
9 patients during 18 exposures 15.63 ± 1.67 J/cm2. These doses are 
equivalent to 26.4 ± 2.6 SED and to 91.9 ± 9.8 SED, respectively. 
One SED is equivalent to 10 mJ/cm2 Commission Internationale de 
l’Eclairage (CIE) erythema-weighted irradiance. In the 15 healthy 
subjects the mean cumulative dose of 9 NB-UVB exposures was 
4.37 ± 0.55 J/cm2, which is equivalent to 25.7 ± 3.2 SED. The cu-
mulative NB-UVB doses given up to 9 exposures to the patients 
with psoriasis and healthy subjects did not differ (p = 0.57).
Measurement of serum 25-hydroxyvitamin D concentrations
Blood samples for serum 25(OH)D measurements were taken 
at baseline, and at 9th and 18th NB-UVB exposures. Follow-up 
samples were taken one month after the NB-UVB course. The 
samples were protected from light, centrifuged and then stored 
at –70ºC. Serum 25(OH)D concentration was analysed in du-
plicates using radioimmunoassay (Immunodiagnostic Systems, 
Boldon, UK), as described previously (23).
Skin biopsies and quantitative real-time PCR
Punch biopsies were taken from skin lesions of 12 patients with 
psoriasis (8 from the buttocks, 2 from elbows, and 2 from lower 
back) and from the buttocks of 13 healthy subjects at baseline 
and at the 9th NB-UVB exposure. The biopsies were immediately 
frozen and stored at –70ºC. Total RNA from biopsies was iso-
lated using TRIsure Reagent (Bioline, Luckenwalde, Germany) 
and 1 µg of RNA was reverse-transcribed with High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster 
City, CA, USA) to cDNA. The mRNA expression levels of 
CYP27A1 and CYP27B1 enzymes, and antimicrobial peptides 
cathelicidin and HBD2 were evaluated using a LightCycler® 2.0 
system and the corresponding human Universal Probe Library 
Set (Roche), as described previously (15).
Statistical analysis 
Statistical comparison between the groups was performed by 
Student’s t-test, permutation test or χ2 test, when appropriate. 
The changes within patients with psoriasis and healthy sub-
jects were analysed by applying a permutation test to related 
samples. Repeated measures were analysed using generalizing 
estimating equation models with the unstructured correlation 
structure using bootstrap-type standard error.
RESULTS
Serum 25(OH)D concentrations at baseline, during and 
after NB-UVB course 
At baseline, serum 25(OH)D concentration was 
74.14 ± 22.9 nmol/l (mean ± SD) in the 12 patients 
with psoriasis and 74.30 ± 14.8 nmol/ in the 15 healthy 
subjects. At 9th NB-UVB exposure serum 25(OH)D had 
increased by 13.2 nmol/l (95% CI 7.2–24.9, p = 0.0029) 
in the patients with psoriasis and by 17.0 nmol/l (95% 
CI 6.7–21.0, p < 0.001) in the healthy subjects (Fig. 1, 
Table II).
At 18th NB-UVB exposure 25(OH)D had increased 
by 49.4 nmol/l (95% CI 35.9–64.6, p = 0.0039) in the 9 
patients with psoriasis (Table II). PASI score improved 
in the patients with psoriasis from 8.7 (range 4.0–16.2) 
at baseline to 6.4 (range 2.1–12.8) at 9th and to 4.5 (range 
1.1–8.2) at 18th exposure (p < 0.001; Table II). 
One month after NB-UVB exposure, serum 25(OH)D 
was still increased from baseline by 29.9 nmol/l (95% 
CI 13.6–49.0; p = 0.0078) in the 8 patients with psoriasis 
and by 17.5 nmol/l (95% CI 10.1–24.9; p < 0.001) in the 
15 healthy subjects (Table II). 
Antimicrobial peptide and enzyme mRNA expression in 
skin biopsy specimens
At baseline, the mRNA expression levels of CYP27A1 
and CYP27B1 were significantly lower (p < 0.001) in 
Table I. Demography and use of oral cholecalciferol before narrow-
band ultraviolet B (NB-UVB) course in 12 patients with psoriasis 
and 15 healthy subjects
Psoriasis 
patients
Healthy 
subjects p-value
Male/female, n 7/5 1/14 0.008
Age, years, mean ± SD 42.8 ± 14 46.1 ± 11 0.47
Body mass index, kg/m2, mean ± SD 29.6 ± 5.4 23.4 ± 3.8 0.002
Fitzpatrick skin type II/III/IV, n 3/6/3 3/10/2 0.66
Oral cholecalciferol, 20 µg daily before
NB-UVB course, months, mean (range) 3.3 (1–24) 3.4 (1–24) 0.75
SD: standard deviation.
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the patients with psoriasis than in healthy subjects (Fig. 
2A and B, Table III). At baseline cathelicidin mRNA 
expression levels were similar in the psoriasis lesions 
and in the normal skin of healthy subjects, whereas 
HBD2 mRNA levels were significantly (p < 0.001) 
higher in the psoriasis lesions (Fig. 2C, Table III).
NB-UVB exposure did not change CYP27A1, 
CYP27B1 and cathelidicin mRNA expression levels in 
the patients with psoriasis, but a significant (p = 0.002) 
decrease was seen in the HBD2 mRNA expression level 
(Fig. 2 and Table III). In the healthy subjects NB-UVB 
exposure significantly decreased CYP27A1, CYP27B1 
and cathelidicin mRNA expression levels, while HBD2 
increased slightly (Fig. 2, Table III). 
DISCUSSION
Several recent studies have demonstrated that NB-UVB, 
a widely used treatment for psoriasis (11), significantly 
improves serum 25(OH)D concentrations, especially 
during the winter (10, 14–17). The number of NB-UVB 
exposures given in these psoriasis studies varied from 15 
to 27 and the increase in serum 25(OH)D ranged from 
66% to 163% (Table IV). In contrast to these previous 
studies, the present patients with psoriasis were additio-
nally supplemented with oral 20 µg of cholecalciferol 
daily for a mean of 3.3 months before entry into the trial. 
Due to this pre-treatment their mean serum 25(OH)D 
was 74 nmol/l at baseline, which is twice as high as in 
our previous study (14). Nevertheless, UVB treatment 
further increased serum 25(OH)D, by 17% at the 9th 
and by 58% at the 18th NB-UVB exposure. Although 
the BMI was significantly lower in the healthy subjects 
than in the patients with psoriasis, the baseline 25(OH)D 
concentration and the increase at 9th NB-UVB exposure 
was of approximately the same magnitude. This finding 
is somewhat unexpected because obese subjects are more 
prone to vitamin D insufficiency due to the deposition of 
vitamin D precursors in fat tissue (2, 24). In a recent study 
(25) in which subjects were supplemented with 15 µg oral 
cholecalciferol daily, BMI in older, but not in younger, 
adults was shown to be negatively associated with the 
change in serum 25(OH)D. These results indicate that 
BMI is important when performing vitamin D studies, 
and vitamin D insufficiency reported in some psoriasis 
studies could be attributed to obesity and comorbidities 
associated with severe psoriasis. The limitation of the 
present study is that the patients with psoriasis and the 
healthy subjects were not matched for BMI. However, 
the similar and significant increases in serum 25(OH)
D levels in both groups who were continuously supple-
mented with a rather high dose of oral vitamin D indicate 
that NB-UVB exposure is an efficient way to improve 
vitamin D balance. In agreement with this, 2 recent 
studies in healthy subjects have documented the superi-
ority of NB-UVB exposure over oral supplementation of 
cholecalciferol, 20 µg and 40 µg daily, to improve serum 
25(OH)D concentration (23, 26).
In the present study the mean increase in serum 
25(OH)D at the 18th NB-UVB exposure was 58% 
and the highest individual concentration measured 
155 nmol/l. Overall, the increase observed was not as 
marked as in previous psoriasis studies (Table IV). This 
is not unexpected, because it appears to be evident that 
the lower the starting 25(OH)D concentration the higher 
Table II. Narrow-band UVB (NB-UVB) doses, serum 25-hydroxyvitamin D (25(OH)D) concentrations and Psoriasis Area Severity Index 
(PASI) scores in 12 patients with psoriasis and 15 healthy subjects
At baseline
At 9th NB-UVB 
exposure
At 18th NB-UVB 
exposure
1 month after 
NB-UVB course
Patients with psoriasis, n
Total NB-UVB dose, J/cm2, mean ± SD
25(OH)D; nmol/l, mean ± SD
PASI score, mean ± SD
12
–
74.1 ± 22.9
  8.7 ± ±3.5
12
  4.5 ± 0.4
87.3 ± ± 16.0
  6.4 ± 3.1
9
15.6 ± 1.7
117.3 ± 28.9
4.5 ± 2.0
    8
–
115.0 ± 26.5
–
Healthy subjects, n
Total NB-UVB dose, J/cm2
25(OH)D, nmol/l, mean ± SD
15
–
74.3 ± 14.8
15
  4.37 ± 0.6
91.3 ± 17.1
–   15
–
  88.3 ± 19.9
Fig. 1. Serum 25-hydroxyvitamin D (25(OH)D) concentrations before and at 
9th (after) narrow-band ultraviolet B (NB-UVB) exposure in 12 patients with 
psoriasis and 15 healthy subjects. The patients with psoriasis and healthy 
subjects received oral cholecalciferol, 20 µg daily. The increase is significant 
in the patients with psoriasis (p = 0.003) and healthy subjects (p < 0.001).
L
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the response to UVB treatment (27). Moreover, there 
is evidence that during UVB exposure to the skin, but 
not during oral supplementation, a negative feedback 
mechanism controls vitamin D synthesis to prevent 
overdosing and vitamin D toxicity (28). It is notewor-
thy in this context, that 1 of the present patients had an 
exceptionally high level of serum 25(OH)D, i.e.130 
nmol/l at baseline and she was the only one to respond 
to NB-UVB exposure with decreased serum 25(OH)D. 
In addition, although the patients and healthy subjects 
continued with oral cholecalciferol supplementation, 
serum 25(OH)D concentrations started to decrease one 
month after NB-UVB exposure. This is in agreement 
with our previous NB-UVB studies (15, 23) and demon-
strates that even rather high continuous oral vitamin 
D supplementation is not sufficient to maintain serum 
25(OH)D levels achieved by a short course of NB-UVB 
exposure. It has been reported that NB-UVB exposure 
given twice a month maintains the levels of 25(OH)
D achieved in the summer (29). Therefore, a similar 
schedule could be applicable to the NB-UVB-treated 
patients with psoriasis during the winter in order to 
maintain sufficient vitamin D.
A previous study in UVB-treated organ cultures sho-
wed that CYP27A1 and CYP27B1 in the keratinocytes 
are capable of hydroxylating precursors into the active 
form of vitamin D, i.e. 1,25(OH)2D (13). Thus, both 
enzymes could be regarded as surrogate markers for 
vitamin D metabolism. In the present study the expres-
sion levels of CYP27A1 and CYP27B1 at baseline were 
low in the psoriatic lesions compared with healthy skin 
and did not change during NB-UVB treatment. At first, 
the low baseline level of CYP27B1 in psoriasis lesions 
seems difficult to explain. However, the patients with 
psoriasis were supplemented with oral cholecalciferol, 
and it could be that the metabolism of vitamin D in the 
psoriasis lesions is far more active than in the normal 
skin of healthy subjects. Due to this, the low CYP27A1 
and CYP27B1 activities in the psoriasis lesions at 
baseline and after NB-UVB exposure, and also in the 
normal skin after NB-UVB exposure, could be due to a 
very sensitive natural feedback controlling mechanism 
in cutaneous vitamin D synthesis (6, 7). 
Antimicrobial peptides seem to have a role in the 
pathogenesis of skin inflammation in psoriasis (21, 30). 
In agreement with our previous study (15), we found 
in psoriasis lesions at baseline significantly increased 
mRNA expression of HBD2. we could also show that 
repeated NB-UVB exposure reduced HBD2 expression 
in healing psoriasis lesions. In contrast to HBD2, we 
found no increased mRNA expression of cathelicidin 
in the psoriasis lesions, either at baseline or after NB-
UVB exposure. This is surprising with regard to the 
findings of our previous study (15). The continuous 
Table III. Vitamin D metabolizing enzyme and antimicrobial peptide mRNA expression levels in the psoriasis lesions of 12 patients and 
normal skin of 13 healthy subjects at baseline and at 9th narrow-band UVB (NB-UVB) exposure
Psoriasis
p-value
Healthy subjects
p-value
Baseline 
Mean ± SD
At 9th NB-UVB 
Mean ± SD
Baseline 
Mean ± SD
At 9th NB-UVB 
Mean ± SD
CYP27A1 0.16 ± 0.85 0.23 ± 0.13 0.17 1.05 ± 0.34 0.43 ± 0.14 < 0.001
CYP27B1 0.69 ± 0.14 0.60 ± 0.18 0.070 1.04 ± 0.35 0.63 ± 0.18 0.0017
Cathelicidin 1.81 ± 1.51 1.70 ± 1.58 0.88 1.32 ± 0.99 0.12 ± 0.08 < 0.001
Human β-defensin-2 41,739 ± 65,700 1,497 ± 1,037 0.002 159.65 ± 302.49 471.84 ± 328.71 0.041
Fig. 2. (A) CYP27A1 mRNA, (B) CYP27B1 mRNA and (C) cathelicidin mRNA expression levels in skin lesions of patients with psoriasis (n = 12) and 
normal skin of healthy subjects (n = 13) before and at 9th (after) narrow-band ultraviolet B (NB-UVB) exposure. Before NB-UVB course the CYP27A1 
and CYP27B1 levels are significantly lower (p < 0.001), but the cathelidicin levels do not differ (p = 0.34) in the patients with psoriasis compared with the 
healthy subjects. NB-UVB exposure did not change CYP27A1 mRNA, CYP27B1 mRNA or cathelidicin mRNA levels in the patients with psoriasis (A: 
p = 0.17; B: p = 0.070; C: p = 0.88) but the decrease is significant (A: p < 0.001; B: p = 0.002; C: p < 0.001) in the healthy subjects.
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oral supplementation with vitamin D before the study, 
with possible accumulation of vitamin D precursors and 
1,25(OH)2D in the psoriasis lesions and activation of 
negative feedback mechanisms, could again be a reason 
for this finding. Overall, the present cathelidicin and 
vitamin D-metabolizing enzyme gene expression results 
suggest that the normal skin of healthy subjects reacts 
more actively to NB-UVB exposure than the inflamed 
skin of psoriasis lesions. It is, however, noteworthy that 
in spite of these gene expression differences the patients 
with psoriasis and healthy subjects showed similar NB-
UVB responses in the serum 25(OH)D concentration. 
Knowledge of the risk of vitamin D insufficiency is 
well-accepted. In Finland, for example, there are recom-
mendations for children and pregnant women to use up 
to 10 µg and for elderly people up to 20 µg daily of oral 
vitamin D supplementation (31). Moreover, vitamin D 
products are actively marketed and voluntary supple-
mentation especially during winter months is now also 
common among dermatological patients. Many patients 
with psoriasis will receive NB-UVB treatment, which is 
effective and, in the short-term, is considered safe with 
regard to risk of skin malignancy (32, 33). The present 
NB-UVB study documented that even though the pa-
tients with psoriasis received oral cholecalciferol 20 µg 
daily their serum 25(OH)D concentrations remained far 
from 250 nmol/l. Levels below this are considered safe 
with regard to toxicity (34) and, therefore, we conclude 
that there is no need to stop voluntary oral vitamin D 
supplementation whenever patients with psoriasis need 
to start NB-UVB treatment. In addition, in the present 
study patients with psoriasis supplemented with oral 
cholecalciferol showed a similar significant decrease 
in PASI score, as did the patients with no oral vitamin 
D supplementation in our previous study (15). This 
suggests that the response to NB-UVB treatment in 
psoriasis is not dependent on whether the patient is 
supplemented with oral vitamin D.
In conclusion, this study showed that, although 
the patients with psoriasis received continuous oral 
cholecalciferol supplementation, NB-UVB exposure 
increased serum 25(OH)D concentration by 58%. In 
healing psoriasis lesions NB-UVB treatment did not 
alter the expression of vitamin D-metabolizing enzyme 
and cathelidicin mRNA, but decreased the expression 
of HBD2 mRNA. 
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